Introduction {#s02}
============

The immune system evolved to fight infection while minimizing host damage. Several regulatory mechanisms are in place to ensure the delicate balance between an effective immune response and the appearance of tissue pathology. An anti-inflammatory response, of which IL-10 is the paradigm, is one such mechanism.

IL-10 ([@bib58]; [@bib161]) is the founding member of a family of cytokines that also includes IL-19, IL-20, IL-22, IL-24, IL-26, IL-28A, IL-28B, and IL-29 (reviewed in [@bib183]). The involvement of IL-10 in many disease states has been demonstrated, both in animal models and in humans with mutations in the IL-10/IL-10R axis (reviewed in [@bib55]; [@bib214]). However, despite considerable progress in IL-10 biology, many outstanding questions still exist. In this review, we revisit the discovery of IL-10, highlight the latest developments toward understanding the metabolic regulation of IL-10 in various cell types, and discuss the molecular signals downstream of the IL-10R in responding cells. We present an overview of the biological functions of IL-10, including some surprising new findings on nonclassical roles for this cytokine. We finish by summarizing the progress made toward the therapeutic manipulation of IL-10.

The discovery of IL-10: A historic perspective {#s03}
==============================================

IL-10 was discovered 30 yr ago as a secreted cytokine synthesis inhibitory factor, produced by T helper (Th) 2 cell clones shown to inhibit cytokine production by Th1 cells ([@bib58]). The mouse and human IL-10--coding genes were subsequently cloned, and the predicted protein sequences were found to be highly homologous to an Epstein--Barr virus--encoded protein, BCRF1 ([@bib161]; [@bib237]). This was the first suggestion that viruses may exploit the inhibitory properties of IL-10 as a mechanism of immune evasion. Indeed, recombinant BCRF1 protein was shown to mimic the activity of IL-10 ([@bib86]), namely inhibition of cytokine synthesis by activated human peripheral blood mononuclear cells and by a mouse Th1 cell clone ([@bib237]). Since then, a number of other viruses have also been shown to encode a homologue of the *Il10* gene ([@bib61]; [@bib119]; [@bib104]). Soon after the discovery of IL-10, its pleiotropic action was unveiled initially in the mouse, not only as a cytokine synthesis inhibitory factor, but additionally as a mast cell ([@bib226]) and thymocyte ([@bib145]) growth factor, and as an activator of B cells ([@bib76]; [@bib200]).

The mechanisms underlying the ability of IL-10 to inhibit cytokine production by Th1 cells were soon unveiled. IL-10--mediated inhibition of IFN-γ secretion by Th1 cells was demonstrated to occur via its action on the APC function of macrophages ([@bib60]) and by its inhibition of cytokine production by activated macrophages and dendritic cells (DC; [@bib15]; [@bib59]; [@bib144]). Additionally, IL-10 inhibited the killing of intracellular pathogens ([@bib68]; [@bib62]; [@bib239]). In complementary studies, IL-10 was shown to prevent antigen-specific proliferation of human T cells by inhibition of the antigen-presenting capacity of monocytes through the down-regulation of class II MHC ([@bib48]). Collectively, these initial studies placed IL-10 as a key mediator of the anti-inflammatory response.

Genetic ablation of *Il10* showed its key role in controlling inflammation in vivo, as IL-10--deficient mice developed colitis ([@bib120]). These findings prompted many genetic association studies between deficiencies in the *IL10* or *IL10R* genes and susceptibility to colitis, an association that is now well acknowledged ([@bib73], [@bib74], [@bib75]; [@bib106]; [@bib163]; [@bib55]; [@bib53]). However, the role of IL-10 clearly exceeds the regulation of intestinal inflammation, as a function for this molecule has been also described in several other settings, from inflammatory or neurodegenerative diseases to infection or cancer (reviewed in [@bib184]; [@bib138]; [@bib183]; [@bib240]).

In summary, IL-10 has emerged as a major suppressor of the immune response and a key player in human disease, and is thus an attractive therapeutic target. However, as discussed below, there is recent evidence that IL-10 may play a previously under-appreciated dual role, in some contexts stimulating the immune response instead of suppressing it. This depends on specific cell types and contexts, thus raising important issues related to its modulation in the clinic and calling for further research into the pleiotropic nature of this cytokine.

Molecular mechanisms regulating IL-10 expression {#s04}
================================================

IL-10--producing cells {#s05}
----------------------

Although Th2 cells were the first identified cellular source of IL-10 ([@bib58]), the production of this cytokine by other CD4 and also CD8 T cells was soon demonstrated ([@bib256]; [@bib225]). We now know that cells of both the myeloid and lymphoid lineages secrete IL-10 in response to different stimuli (reviewed in [@bib203]; [@bib183]). This includes macrophages, monocytes, DCs, neutrophils, mast cells, eosinophils, and natural killer cells, in addition to CD4 and CD8 T cells and B cells (reviewed in [@bib162]; [@bib63]). More recently, the group of IL-10--producing cells was expanded to resident macrophages, such as microglia (reviewed in [@bib138]) and cardiac macrophages ([@bib88]). Notably, some nonhematopoietic cells, including epithelial cells, are also able to produce IL-10 ([@bib103]). Finally, tumor cells can also produce IL-10, which has been correlated with their ability to cause immunosuppression ([@bib31]; [@bib99]).

The regulation of IL-10 production: Global concepts {#s06}
---------------------------------------------------

The expression of IL-10 is tightly regulated to avoid diseases related to its excess or deficiency. Both common and cell-specific regulatory mechanisms including the triggering of specific signaling pathways, the expression and activation of particular transcription factors, and post-transcriptional and epigenetic regulation ensure the appropriate production of IL-10 (reviewed in [@bib203]; [@bib63]; [@bib183]). In myeloid cells, the expression of IL-10 accompanies that of pro-inflammatory cytokines, downstream of the activation of multiple pattern recognition receptors (PRRs; reviewed in [@bib203]; [@bib202]; [@bib64]; [@bib183]). MAPK are among the key pathways regulating IL-10. Activation of ERK1/2 downstream of the MAP3 kinase tumor progression locus 2 (Tpl2) regulates the expression of *Il10* by TLR-activated macrophages and DCs, as shown by the reduction of IL-10 production observed in Tpl2-deficient or upon chemical inhibition of ERK1/2 in macrophages ([@bib254]; [@bib11]; [@bib136]; [@bib107]). The MAPK p38 is also activated downstream of TLR signaling and shown to regulate IL-10 production by these cells ([@bib254]; [@bib32]; [@bib111]). Several transcription factors known to regulate the transcription of the *Il10* gene in macrophages and DCs are activated downstream of ERK1/2 or p38, as is the case for cAMP response element binding protein (CREB), cyclic AMP-dependent transcription factor 1 (ATF1), cFos, and Sp1 (reviewed in [@bib203]; [@bib202]; [@bib64]; [@bib183]). Cooperation between ERK and p38 activates the mitogen- and stress-activated protein kinase 1 (MSK1) and MSK2, which promote IL-10 production in TLR4-stimulated macrophages, through the transcription factors CREB and ATF1 ([@bib4]). The regulation of IL-10 by MSK/CREB has been further demonstrated in the context of the activation of TLR2 in intestinal macrophages by a *Helicobacter hepaticus*--derived polysaccharide ([@bib45]). NF-κB activation downstream of PRR also regulates IL-10 production in myeloid cells. Specifically, binding of several NF-κB family members to the *Il10* locus promote IL-10 production in TLR4-stimulated macrophages ([@bib109]; [@bib204]; [@bib26]). Crosstalk between the NF-κB p105 subunit and Tpl2 has also been reported ([@bib11]). Finally, the phosphoinositide-3-kinase (PI3K)/serine/threonine protein kinase B (Akt) cascade also regulates the expression of *Il10* in macrophages by blocking the kinase glycogen synthase kinase 3β, which inhibits IL-10 production ([@bib181]; [@bib173]), and conversely potentiating IL-10 production through ERK1/2 ([@bib149]) and mechanistic target of rapamycin (mTOR; [@bib181]; [@bib245]) activation. Thus, activation of ERK1/2 is at the crossroads of several other signaling cascades, demonstrating its importance as a central pathway for *Il10* gene regulation in myeloid cells. In addition to direct PRR signaling, coreceptors and other cytokines regulate IL-10 production by macrophages and DCs. CD40, dectin-1, and DC-specific intercellular adhesion molecule-3--grabbing non-integrin enhance PRR-induced IL-10 (reviewed in [@bib203]; [@bib202]; [@bib64]; [@bib183]). Similarly, type I IFN has been shown to potentiate IL-10 production by LPS-stimulated ([@bib28]; [@bib85]) and *Mycobacterium tuberculosis*--infected ([@bib157]) bone marrow--derived macrophages. Mechanistically, type I IFN induces transcription of the *Il10* gene and stabilizes the resulting mRNA, via STAT1 and ERK activation ([@bib85]).

IL-10 is produced by all T cell subsets. In CD4 Th cells, IL-10 production accompanies that of the hallmark cytokines IFN-γ, IL-4/IL-5/IL-13, and IL-17 (reviewed in [@bib203]; [@bib202]; [@bib64]; [@bib183]). IL-10 production occurs downstream of TCR triggering, which activates Ras and subsequently MAPK ERK1/2 and AP1, which enhance *Il10* transcription ([@bib105]; [@bib241]; [@bib205]). Transcription factors of the NFAT family also promote IL-10 production by T cells ([@bib96]; [@bib129]). Additionally, STAT4, 6, and 3 activation during Th1, Th2, or Th17 CD4 T cell differentiation, respectively, have been suggested to contribute to *Il10* gene expression ([@bib205]), as have the basic leucine zipper ATF-like transcription factor and interferon regulatory factor (IRF) 4, which are critical for Th2 and Th17 differentiation ([@bib33]; [@bib71]; [@bib133]). Therefore, the mechanisms required for the differentiation and activation of Th cells seem to be required for regulation of IL-10 production, ensuring a feedback regulatory loop to limit immune pathology. In further support of this, the Th2 and Th17 cell lineage transcription factors GATA binding protein 3 (GATA3) and retinoid-related orphan receptor γt, respectively, have been described to modulate IL-10 production by CD4 T cells. GATA3 binds the *Il10* promoter, inducing histone acetylation and remodeling the *Il10* locus to facilitate *Il10* gene expression ([@bib212]; [@bib29]), although it is not required for IL-10 production by differentiated Th2 cells ([@bib264]). In contrast, the Th17-associated transcription factor RORγt has been described to repress IL-10 production by Th17 cells ([@bib33]). Several reports attest to the importance of PR domain zinc finger protein 1 (Blimp-1) in the regulation of IL-10 production by T cells (reviewed in [@bib202]; [@bib183]). Blimp-1 is induced by STAT4 downstream of the IL-12R and shown to be absolutely required for IL-10 expression by IL-12--driven effector Th1 cells both in vitro and in vivo ([@bib177]). Furthermore, the induction of IL-10 by IL-27 in CD4 T cells requires Blimp-1 ([@bib177]), likely downstream of STAT1/STAT3 signaling ([@bib218]). IL-27 together with TCR triggering induced the differentiation of naive T cells into IL-10--producing type 1 regulatory T cells (Tr1; [@bib191]). The induction of IL-10 in Tr1 cells is dependent on the cooperation between the transcription factors Eomes and Blimp-1 ([@bib259]). Of note, in vitro generation of Tr1 cells in the presence of TGF-β, in addition to IL-27, shifts the transcriptional requirements from Blimp-1 to cMaf and aryl hydrocarbon receptor (AhR; [@bib6]; [@bib177]). Blimp-1 is also required for IL-10 expression by CD8 T cells ([@bib219]).

Recent data place the leucine zipper transcription factor cMaf as a master regulator of IL-10 production, common to both myeloid and T cells (reviewed in [@bib203]; [@bib63]; [@bib202]; [@bib183]). cMaf was initially shown to bind to the *Il10* promoter and enhance gene transcription in TLR4-stimulated macrophages ([@bib22]). More recently, several studies support a role of cMaf in also regulating T cell--derived IL-10 in vitro ([@bib252]; [@bib6]; [@bib33]; [@bib64]). IL-10 production in vivo by Th1, Th2, and Th17 cells in experimental disease models requires cMaf ([@bib64]). A link between cMaf and IL-10 expression by human Tr1 and Th17 cells has also been proposed ([@bib66]; [@bib7]). cMaf cooperates with other transcription factors to regulate IL-10 expression. cMaf may require Blimp-1 to enhance IL-10 production by Th1 cells ([@bib177]). Although not absolutely required, the transcription factor AhR allows maximal IL-10 production by LPS-stimulated macrophages ([@bib112]) and T cells, where it directly binds to cMaf and synergistically transactivates the *Il10* gene promoter ([@bib6]). The transcription factor Bhlhe40 has been recently revealed as a repressor of IL-10 production in T cells. Mice deficient in Bhlhe40 are resistant to the development of experimental autoimmune encephalomyelitis, presumably by increasing the IL-10 production by Th1 and Th17 pathogenic cells ([@bib134]). Targeted deletion of Bhlhe40 in either CD4 T cells or CD11c^+^ cells correlated with increased IL-10 and decreased IFN-γ production and resulted in increased bacterial burdens during infection with *M. tuberculosis*, rendering Bhlhe40-deficient mice more susceptible to infection ([@bib94]). Additionally, Bhlhe40 is a molecular switch for IL-10 production in Th1 cells and as a result, mice with conditional deletion of Bhlhe40 in T cells succumbed to *Toxoplasma gondii* infection ([@bib257]). In both T cells and bone marrow--derived DCs, Bhlhe40 binds to a characterized enhancing region of the *Il10* locus ([@bib94]), where the activating transcription factors AP1 ([@bib105]) and IRF4 ([@bib1]) have been shown to bind. The opposing effects of Bhlhe40 and cMaf on the regulation of IL-10 may result from the interaction between these two transcription factors. In the absence of cMaf, up-regulation of *Bhlhe40* in T cells has been described ([@bib64]); conversely, deficiency of Bhlhe40 resulted in the up-regulation of *Maf* ([@bib257]). Very recently, in macrophages, Bhlhe40 has been shown to bind to promoter elements of the *Maf* gene, repressing its transcription ([@bib102]).

Metabolic regulation of IL-10 production {#s07}
----------------------------------------

Recent findings show a metabolic reprogramming of immune cells in response to environmental cues ([@bib180]). In response to LPS and other stimuli, the metabolic profile of macrophages and DCs shifts toward glycolysis, with the accumulation of metabolites such as citrate and succinate that in turn regulate cytokine gene expression ([@bib180]). IL-10 is no exception, its production being regulated by alterations in the cell metabolic networks, as well as by specific metabolites ([Fig. 1 A](#fig1){ref-type="fig"}). The LPS-induced metabolic regulator pyruvate kinase isozyme M2 (PKM2) was shown to inhibit the cellular glycolytic reprogramming, succinate accumulation, and IL-1β production, while favoring IL-10 production by macrophages ([@bib185]). Similarly, inhibition of the glycolytic shift promoted by *M. tuberculosis* infection of macrophages was shown to increase IL-10 production, while decreasing that of IL-1β ([@bib72]). In a different setting, macrophages activated by efferocytosis during wound injury up-regulated their production of IL-10 via the SIRTUIN1 signaling cascade and the transcription factor PBX1, driven by the respiratory chain ([@bib260]). In an experimental model of colitis, chemical inhibition of the nicotinamide phosphoribosyltransferase enzyme reduced mucosal nicotinamide adenine dinucleotide levels and the activities of nicotinamide adenine dinucleotide--dependent enzymes, while favoring the polarization of monocyte/macrophages toward IL-10 production ([@bib70]). IL-10 production by DCs is also modulated by metabolic pathways. Several metabolites, such as butyrate, adenosine, ATP, or lactic acid, have been proposed to favor IL-10 production by DCs ([@bib132]; [@bib174]; [@bib215]). Furthermore, activation of mTOR, a central integrator of cellular metabolism, in DCs has been shown to enhance IL-10 ([@bib23]; [@bib2]; [@bib16]; [@bib90]). Adiponectin also enhances IL-10 production by DCs through a pathway that depends on the cellular energy sensor AMP-activated protein kinase (AMPK; [@bib224]). Moreover, a recent study showed that in DCs stimulated with zymozan, the production of IL-10 depended on the maintenance of pyruvate flux, as it reinforces the presence of acetylated histone 3 molecules bound to the *Il10* gene promoter ([@bib148]).

![**IL-10 production is metabolically regulated. (A)** Macrophages stimulated via TLR4 undergo a metabolic reprogramming toward glycolysis, which leads to the production of lactate and also to a break of the TCA cycle. As a result, succinate accumulates and activates HIF-1α, and the transcription of the *Il1b* gene is enhanced. Inhibition of this reprogramming, via the metabolic regulator PKM2 or during infection with *M. tuberculosis*, inhibits *Il1b* gene transcription, while promoting that of *Il10*. An increase of IL-10 production as a result of enhanced fatty acid metabolism has also been described, and is mediated by the transcription factor PBX1. In DCs, the maintenance of the pyruvate flux downstream of zymosan stimulation has been shown to reinforce the presence of acetylated histone 3 at the *Il10* gene promoter, thus favoring IL-10 production. Other metabolic regulators, such as AMPK and mTOR, and metabolites, such as ATP, lactate, or butyrate, also contribute to IL-10 production by DCs, in different settings, but the molecular mechanisms in place remain largely unknown. **(B)** Gut microbiota derived short chain fatty acids signal through GPR43 and activate STAT3 and mTOR in differentiated Th1 cells, up-regulating the expression of Blimp-1 and consequently that of IL-10. In IL-27--induced Tr1 cells, IL-27R signaling induces the oxysterol 25-hydroxycholesterol (25-OHC). 25-OHC activates liver X receptor (LXR) and presumably decreases the expression of the transcription factor Blimp-1, thus limiting the expression of the *Il10* gene. In IL-27--differentiated Tr1 cells, extracellular ATP (eATP) has been shown to increase the amounts of HIF-1α and consequently reduce those of AhR. This stabilization of HIF-1α also occurs under hypoxic conditions. Given the role of AhR in enhancing IL-10 expression in Tr1 cells, HIF-1α stabilization ultimately decreases IL-10 production. The Th1 switching from IFN-γ single-producing cells, to IFN-γ/IL-10 double-producing ones, and eventually IL-10 single-producing cells, is coupled to the biosynthesis of cholesterol, via cMaf. In Th17 cells, a short chain fatty acid, pentanoate, has been suggested to inhibit AMPK activation, thus releasing the mTOR pathway, increasing the glycolytic flux, and leading to the production of IL-10. In parallel, through an epigenetic-mediated mechanism, pentanoate reduces IL-17A expression.](JEM_20190418_Fig1){#fig1}

T cell immunity also relies on metabolic reprogramming ([@bib19]), but how this affects IL-10 production is only now starting to be understood ([Fig. 1 B](#fig1){ref-type="fig"}). Initial evidence for this came from the finding that extracellular ATP or hypoxia induces the transcription factor HIF-1α in Tr1 cells, which in turn down-regulates AhR and IL-10 production ([@bib6]; [@bib150]). In addition, oxysterols, oxidized forms of cholesterol produced downstream of the IL-27R, negatively regulate IL-10 secretion in Tr1 cells via activation of the liver X receptor signaling and possibly through inhibition of the IL-10--inducing transcription factor Blimp-1 ([@bib238]). Furthermore, inhibition of cholesterol biosynthesis blocked the induction of cMaf and consequently IL-10 production by IFN-γ--producing Th1 cells ([@bib189]). Finally, the short-chain fatty acid pentanoate has been shown to induce IL-10 production in lymphocytes by reprogramming their metabolic-epigenetic crosstalk toward elevated glucose oxidation, while in parallel suppressing Th17 cells ([@bib143]). Of note, in the same study, pentanoate has been shown to enhance *Il10* gene expression in regulatory B cells ([@bib143]). Interestingly, gut microbiota--derived short-chain fatty acids have also been shown to induce Th1 cells to produce IL-10 to maintain intestinal homeostasis, through the activation of STAT3 and mTOR, upstream of Blimp-1 up-regulation ([@bib220]). Despite these studies, the molecular mechanisms concerning IL-10 regulation by metabolic changes or metabolites across different subsets of T cells remain elusive. However, careful interpretation of experiments should be exercised. Indeed, findings from a recent study show that the widely used glucose analogue 2-deoxyglucose inhibited IL-10 production by Th1, Th2, and Th17 cells not through the inhibition of glycolysis, but instead through the modulation of glycosylation on cell surface proteins ([@bib64]).

The regulation of IL-10 in other cell types {#s08}
-------------------------------------------

In contrast to macrophages/DCs and T cells, the mechanisms regulating IL-10 in other cells are less explored and understood. IL-10 production by PRR-stimulated microglia follows the general basic mechanisms seen in peripheral myeloid cells (reviewed in [@bib138]). Molecules present in the microenvironment, such as adenosine, ATP, or glutamate, have been described to potentiate IL-10 production by microglia, but the precise mechanisms underlying these effects are mostly unknown ([@bib209], [@bib210]; [@bib246]; [@bib118]; and reviewed in [@bib138]). Furthermore, other cytokines may impact IL-10 secretion by microglia. Although the effect of IFN-γ in regulating microglia-derived IL-10 is still controversial ([@bib234]; [@bib98]), type I IFN has been shown to up-regulate IL-10 in PRR-induced microglia ([@bib139]), similar to what has been described for bone marrow--derived macrophages (reviewed in [@bib183]).

The regulation of IL-10 production by epithelial cells is also not fully understood. Engagement of CD1d on intestinal epithelial cells has been shown to induce IL-10 ([@bib34]), via a mechanism that involves the activation of STAT3 and STAT3-dependent transcription of IL-10 ([@bib182]). Crosstalk between TLR4-activated macrophages and intestinal epithelial cells has also been shown to sustain the expression of IL-10 in the latter, by the action of nuclear receptor peroxisome proliferator-activated receptor γ ([@bib95]). Furthermore, microbial and/or environmental oxazoles have been shown to induce tryptophan-derived metabolites and activate AhR in intestinal epithelial cells. The activated AhR in turn limits CD1d-restricted production of IL-10 by these cells ([@bib101]). Thus, metabolites in the intestine regulate IL-10 production. Given the importance of intestinal epithelial cells in maintaining the intestinal barrier and of IL-10 in controlling intestinal inflammation, more research in this area is needed.

The effects of IL-10 in responding cells {#s09}
========================================

The IL-10R signaling cascade in brief {#s10}
-------------------------------------

The cellular response to IL-10 depends on engagement of the IL-10R and intracellular signaling cascades ([Fig. 2](#fig2){ref-type="fig"}). IL-10, as the other family members, signals through a heterodimeric receptor ([@bib190]). In the case of IL-10, the receptor is composed two subunits: the high-affinity IL-10Rα, mainly expressed in leukocytes, and the ubiquitously expressed IL-10Rβ, which is shared by the receptor complex of other IL-10 family members (reviewed in [@bib258]; [@bib183]). The intracellular signaling cascades downstream of the IL-10R have been described in detail in previous reviews ([@bib50]; [@bib168]; [@bib184]). Building upon the extensive literature in this topic, an IL-10/IL-10R signaling map has been assembled ([@bib233]).

![**The anti-inflammatory response initiated downstream of the IL-10R.** Binding of IL-10 to its receptor activates a major JAK1-TYK2-STAT3 signaling cascade, which culminates with the induction of the STAT3-mediated anti-inflammatory response. The STAT3 transcriptional reprogramming results in a number of molecules that include transcriptional repressors, chromatin modifiers, and post-transcriptional or post-translational regulators. Together, these molecules will limit the inflammatory response induced for example downstream of PRR activation. Recently, IL-10 has been shown to modulate the transcription of several metabolic regulators, including DDIT4, in a STAT3-dependent way. As DDIT4 is a regulator of mTORC, the IL-10R signaling limits the glycolytic flux downstream of TLR4 activation, which in turn controls the inflammatory response of the macrophage. In addition to the JAK-STAT3 pathway, STAT1, STAT5, and the PI3K-Akt cascade have also been reported to mediate IL-10 responses. The metabolic regulator AMPK has been reported to activate the PI3K-Akt-mTORC cascade, but also STAT3, in response to IL-10. STAT3 is moreover activated downstream of receptors for other IL-10 family cytokines, IL-6, and a number of other cytokines and growth factors. How the cell distinguishes the anti- from the pro-inflammatory reprogramming downstream of STAT3 activation is not fully understood, but the IL-10--induced SOCS3 has been reported to play an important role by blocking STAT3 at least downstream of the IL-6R, but not of the IL-10R. DUSP, dual-specifity phosphatase; Gsk3β, glycogen synthase kinase 3β; Sbno2, protein strawberry notch 2; TTP, tristetraprolin.](JEM_20190418_Fig2){#fig2}

Engagement of the IL-10Rα leads to its oligomerization with the IL-10Rβ subunit ([@bib255]). This in turn allows the phosphorylation of JAK1 associated with the IL-10Rα subunit and of tyrosine kinase 2 (TYK2) associated with the IL-10Rβ subunit ([@bib199]; [@bib198]). These kinases further phosphorylate two functional tyrosine residues on the intracellular domain of the IL-10Rα, needed for the recruitment of STAT3 ([@bib243]). Activation of STAT3 by its phosphorylation allows its translocation to the nucleus, with the initiation of a specific transcriptional program that largely defines the IL-10--mediated anti-inflammatory response ([@bib223]; [@bib123]; [@bib248]; reviewed in [@bib168]; [@bib92]). In addition to the JAK/STAT3 pathway, the signaling cascade PI3K/Akt/GSK3β has also been shown to mediate IL-10--induced transcription in macrophages ([@bib39]; [@bib5]). Furthermore, IL-10 stimulation of primary monocytes results in PI3K-mediated mTORC1 activity ([@bib39]). Interestingly, IL-10 activation of the both STAT3 and PI3K/Akt/mTORC1 pathways in macrophages was shown to require AMPK ([@bib265]). Of note, activation of STAT1 and STAT5 downstream of the IL-10R has also been reported ([@bib130]; [@bib244]; [@bib193]; [@bib54]).

Interestingly, STAT3 activation has also been described for other cytokines in addition to IL-10, most notably IL-6 ([Fig. 2](#fig2){ref-type="fig"}). It is surprising that both pro- and anti-inflammatory cytokines may signal through the same molecule even in the same cell type, despite inducing profoundly different responses, and resulting in a different gene activation program (reviewed in [@bib167], [@bib169]; [@bib92]). A likely explanation for this apparent paradox relies on the cooperation of STAT3 with selective cofactors to deliver a different gene expression program. One such cofactor is the suppressor of cytokine signaling 3 (SOCS3), which, despite being induced by both IL-10 and IL-6 in macrophages, only suppresses the activity of the IL-6R (gp130; [@bib41]; [@bib124]). Indeed, the IL-10R appears refractory to the effects of all members of the SOCS family ([@bib249]). Additionally, it is possible that in response to different stimuli, the epigenetic landscape of the STAT3-regulated genes changes, thus allowing for selective transcription of anti-inflammatory or inflammatory mediators (reviewed in [@bib167], [@bib169]; [@bib92]).

Molecular basis for IL-10/STAT3 anti-inflammatory activities {#s11}
------------------------------------------------------------

As discussed above, a wealth of data positions the IL-10/STAT3 axis as a major transcriptional inhibitor of genes encoding cytokines, chemokines, cell-surface molecules, and other molecules required for a full immune response ([@bib166]; reviewed in [@bib168]). The requirement for STAT3 as a mediator of IL-10 responses is well-established ([@bib223]; [@bib123]; [@bib248]). Macrophage/neutrophil-restricted deletion of STAT3 mimics IL-10 deficiency itself, resulting in the development of enterocolitis and high susceptibility to LPS-mediated shock and septic peritonitis ([@bib223]; [@bib115]; [@bib151], [@bib152]). How STAT3 activation results in the anti-inflammatory activity of IL-10 is not fully understood ([Fig. 2](#fig2){ref-type="fig"}).

Several independent reports performed over the years globally show that STAT3 acts indirectly by inducing the expression of a series of genes that execute the inhibitory effects associated with an anti-inflammatory response (reviewed in [@bib92]). Among the STAT3-dependent anti-inflammatory mediators are several transcription factors, such as the E26 transformation--specific family transcriptional repressor, ETV3, and a helicase family corepressor, Strawberry notch homologue 2, that inhibit NF-κB--mediated transcription in LPS-stimulated macrophages ([@bib52]); and Nfil3, which negatively regulates the production of IL-12p40 by LPS-stimulated myeloid cells ([@bib216]). Other molecular targets of IL-10--activated STAT3 have been described, including the up-regulation of the dual-specificity phosphatase 1, which impairs the inflammatory response of LPS-induced macrophages by down-regulating the activity of the MAPK p38 ([@bib83]). Also, in LPS-stimulated macrophages, a link between IL-10/STAT3 and the induction of the RNA destabilizing factor tristetraprolin has been proposed, and shown to be mediated by a delayed activation of p38 MAPK, resulting in diminished mRNA and protein levels of proinflammatory cytokines ([@bib207]). Finally, in LPS-activated macrophages, IL-10 was shown to inhibit the transcription of the microRNA miR-155 in a STAT3-dependent manner, leading to increased expression of SH2 domain-containing inositol 5′-phosphatase 1 (SHIP1; [@bib155]), a negative regulator of TLR signaling ([@bib3]). Subsequently, SHIP1 was shown to inhibit TNF translation in LPS-activated macrophages through an IL-10--dependent, STAT3-independent mechanism ([@bib27]). Of note, IL-10 induction of miR-155 was also shown to regulate the expression of Aicda, a critical component of antibody class-switching in B cells ([@bib56]).

Two genome-wide studies were performed to reveal the universe of STAT3-regulated genes. The obtained data support a model of indirect STAT3 action in response to IL-10. The first study integrated STAT3 chromatin immunoprecipitation, RNA-sequencing, and computational approaches performed in IL-10--treated resting or LPS-stimulated macrophages ([@bib91]). The second study used chromatin immunoprecipitation sequencing to analyze the binding of STAT3 at the genomic level in DCs following histone deacetylases inhibition ([@bib221]). Regardless of the critical role of STAT3 in mediating the response downstream of the IL-10R, it is possible that the STAT3 pathway may not be sufficient to mediate the full action of IL-10. Other anti-inflammatory mediators have been described downstream of the IL-10R, but their dependency on STAT3 is as yet unclear. Such is the case for Bcl3, which inhibits TNF production in LPS-treated macrophages via impairment of NF-κB ([@bib121]) and A20-binding inhibitor of NF- κB activation 3, which attenuates NF-κB signaling in human but not mouse macrophages ([@bib242]). IL-10--induced heme-oxygenase 1 has also been shown to contribute to the anti-inflammatory response triggered in macrophages ([@bib128]).

Some lines of evidence suggest that chromatin accessibility might also be a mechanism of regulation of gene expression by the IL-10/STAT3 axis. For example, HDAC4, which acts as a repressor of gene expression by deacetylating histones, was identified as a STAT3 target ([@bib91]). Furthermore, in adipose tissue, IL-10 has been shown to repress transcription of thermogenic genes by altering chromatin accessibility in a STAT3-dependent manner ([@bib194]).

Classic roles of IL-10 {#s12}
----------------------

In addition to being produced by many different cell types, IL-10 functionally targets diverse cells, resulting in a broad anti-inflammatory activity. As compared with most other cell types, macrophages express higher levels of the IL-10R ([@bib162]). Compelling evidence provided by the study of cell-restricted IL-10R deficiency has pointed to macrophages being the main targets of the IL-10 inhibitory effects ([@bib213]; [@bib266]). Indeed, soon after its discovery, IL-10 was shown to trigger a robust immune suppressive response in macrophages and other APCs, mainly via the transcriptional inhibition of cytokines and chemokines, as well as of MHCII, and costimulatory and adhesion molecules ([@bib15]; [@bib47],[@bib48]; [@bib59],[@bib60]; [@bib49]; [@bib43]; [@bib247]; [@bib40]). Overall, IL-10 both modulates the local cytokine micro-environment and limits antigen presentation, thus preventing the efficient development of T cell responses. Additionally, IL-10 also limits basic microbicidal mechanisms, namely the induction of nitric oxide synthase and the production of nitric oxide, as well as the release of reactive oxygen intermediates ([@bib15]) by murine macrophages stimulated through PRR in the context of IFN-γ ([@bib42]).

The suppressive effect of IL-10 appears to be targeted to specific genes. This is well illustrated by a gene expression screen for IL-10--induced genes performed in LPS-stimulated macrophages, which identified a 15--20% inhibition of the LPS-induced genes ([@bib123]). A more recent study further elucidated the mechanisms underlying the suppressive activity of IL-10 in LPS-stimulated macrophages, through genome-wide approaches. In line with previous reports, inhibition of transcription was found to be the primary mechanism for IL-10--mediated suppression ([@bib36]). Novel targets of IL-10 in macrophages have been recently revealed, including the modulation of the macrophage metabolic reprogramming downstream of TLR4 activation ([@bib97]). Specifically, IL-10 inhibited LPS-induced glucose uptake and glycolysis, promoting a shift toward oxidative phosphorylation ([@bib97]).

Inhibition of cytokine and chemokine production by IL-10 is also documented for neutrophils ([@bib25]; [@bib110]) and for resident macrophages, such as microglia ([@bib10]; and reviewed in [@bib138]). However, and most interestingly, the comparison of the anti-inflammatory response induced by IL-10 across different LPS-stimulated myeloid cells showed a divergent pattern. Specifically, in macrophages, IL-10 mostly inhibited NF-κB target genes, whereas in DCs and mast cells, an indirect disruption of IRF was proposed, and in neutrophils, IL-10 appeared to induce both IRF disruption and indirect NF-κB inhibition ([@bib93]).

Classically, IL-10 is known to inhibit T cell responses via APCs ([@bib144]). However, IL-10 can also limit T cell responses by acting directly on CD4 T cells to induce nonresponsiveness or anergy ([@bib78]). More recently, IL-10 has been shown to act directly on memory/effector T cells ([@bib108]) in experimental colitis, in Th17 cells during intestinal inflammation ([@bib87]), and in Th2 cells in a murine model of house dust mite allergy ([@bib37]). Surprisingly, IL-10--stimulatory effects on T cells have also been described. IL-10 enhances CD8 T cell proliferation, cytotoxic activity, and IFN-γ production ([@bib79]; [@bib164]; [@bib172]). IL-10 promotes the survival and action of Foxp3 regulatory T cells ([@bib165]; [@bib30]). Stimulatory activities of IL-10 on mast cells and B cells have also been well documented ([@bib226]; [@bib200]; [@bib100]).

Nonclassic roles of IL-10 {#s13}
-------------------------

Although the effects of IL-10 have been classically studied in immune cells, the range of IL-10--responding cells is expanding ([Fig. 3](#fig3){ref-type="fig"}). It is now evident that IL-10 also acts in nonhematopoietic cells, where it plays important homeostatic roles. An example of this comes from central nervous system (CNS) and peripheral nervous system cells, which respond to IL-10 and other IL-10 family members (reviewed in [@bib138]; [@bib20]). In this context, IL-10 plays important roles in limiting neuronal damage during infection or other inflammatory processes, as well as in regulating homeostatic processes. IL-10 has been associated with increased neuronal survival ([@bib262],[@bib263]) and the regulation of adult neurogenesis ([@bib187]; [@bib186]). Administration of IL-10 in different settings proved beneficial for axon regeneration, through mechanisms that implicate STAT3 and the regulation of NF-κB signaling (reviewed in [@bib236]). Finally, IL-10 was shown to reduce vulnerability of neurons to CNS ischemia and trauma ([@bib114]; [@bib77]). Importantly, whether the effects of IL-10 on neurons and oligodendrocytes are direct or indirect is still controversial. To support a direct effect on cells of the CNS, resting astrocytes express the IL-10R and respond to IL-10 ([@bib160]; [@bib127]; [@bib251]; [@bib188]). IL-10 limits reactive astrogliosis in response to pathogens and promotes the expression of TGF-β by astrocytes ([@bib10]; [@bib178]; and reviewed in [@bib20]). At the organismal level, variations in IL-10 expression have been associated with altered depressive-like behavior. IL-10--deficient female mice displayed increased depressive-like behavior, whereas IL-10--overexpressing mice displayed a decreased depressive-like behavior ([@bib158]). More research is clearly needed to fully elucidate how IL-10 regulates the CNS in health and disease.

![**Nonclassic roles of IL-10.** The functions of IL-10 surpass its effects in immune cells. IL-10 plays an important role in the CNS, limiting the damage effects of neuroinflammation, but also contributing to several homeostatic processes. The molecular mechanisms operating in neurons or astrocytes in response to IL-10 remain elusive, but STAT3 and SOCS3 activation, as well as NF-κB, regulation have been proposed. Bone marrow--derived IL-10 activates the IL-10R/STAT3 signaling cascade, altering the chromatin landscape and the transcription factor occupancy at regulatory regions of thermogenic genes. The thermogenic gene expression is thus repressed and the energy expenditure limited. As a result, mice lacking IL-10 are protected against diet-induced obesity. In epithelial cells, IL-10 has been recently associated with wound healing. This is particularly important in intestinal epithelial cells (IECs), where the underlying mechanisms are starting to be unveiled. In response to IFN-γ, the enzyme 2,3-dioxygenase 1 (IDO1) catalyses the conversion of tryptophan (Trp) to kynurenine (Kyn), which activates the AhR, thus inducing the transcription of the IL-10Rα subunit. Activation of the IL-10R in response to macrophage-derived IL-10 leads to the STAT3-dependent CREB activation and the transcription of WSP-1, a promoter of epithelial cell proliferation and repair.](JEM_20190418_Fig3){#fig3}

Another nonclassic function ascribed to IL-10 relates to its regulation of adipose tissue ([Fig. 3](#fig3){ref-type="fig"}). Epidemiological studies link a low production of IL-10 with metabolic syndrome and type 2 diabetes ([@bib232]), but in animal models, ablation of IL-10 did not support an anti-obesity function for this cytokine ([@bib46]; [@bib159]; [@bib153]). However, previous studies proposed that IL-10 might promote the activity of M2 macrophages in adipose tissue ([@bib142]; [@bib84]; [@bib67]; [@bib250]), or act directly on adipocytes to decrease their inflammatory response ([@bib135]). Very recently, and contrary to the previously established idea that IL-10 might stimulate brown tissue activity by limiting inflammation, direct IL-10 signaling in adipocytes was strikingly shown to limit thermogenesis and energy expenditure ([@bib194]). Mechanistically this effect involved remodeling the chromatin landscape of adipocytes and specific transcriptional down-regulation of thermogenic genes ([@bib194]). As a result, mice lacking IL-10 had increased energy expenditure and were protected against diet-induced obesity ([@bib194]). It will be interesting in future to evaluate the therapeutic value of IL-10 manipulation in obesity, taking all these findings into consideration.

The last "nonclassic" role of IL-10 that we will discuss relates to its function as a promoter of epithelial wound repair ([Fig. 3](#fig3){ref-type="fig"}). Several studies highlight the IL-10--mediated pro-repair activities, which have been classically attributed to its anti-inflammatory activities (reviewed in [@bib222]). However, this concept is changing, and an effect of IL-10 as a regulator of the extracellular matrix and fibroblast function is emerging ([@bib9]; and reviewed in [@bib113]). Similarly, the critical role of IL-10 in gut homeostasis is well documented, with the majority of the studies focusing on its anti-inflammatory activities (reviewed in [@bib116]). Recent evidence reveals an additional role for IL-10 as an orchestrator of epithelial wound repair ([@bib140]); however, the molecular bases for this are only starting to be unveiled. Macrophage-derived IL-10 was shown to activate CREB signaling in intestinal epithelial cells, leading to the secretion of the WNT1-inducible signaling protein 1, which in turn induced epithelial cell proliferation and wound closure ([@bib192]). Furthermore, up-regulation of the IL-10R in intestinal epithelial cells has been described ([@bib117]), and recent studies not only confirm the importance of the IL-10R in wound healing but also implicate tryptophan metabolites and AhR in its up-regulation ([@bib125]).

Therapeutic manipulation of IL-10 {#s14}
=================================

Given the wide spectrum of the anti-inflammatory properties attributed to IL-10, therapeutic manipulation of this cytokine has attracted a great deal of interest (reviewed in [@bib179]; [@bib183]; [@bib240]). We next discuss the therapeutic opportunities for IL-10 in various pathologies, and the strategies used to manipulate IL-10 levels in the organism ([Fig. 4](#fig4){ref-type="fig"}).

![**The potential of enhancing IL-10 to treat disease.** Several IL-10 enhancing strategies have been tried in a number of diseases and models of disease. The best understood effects of IL-10 at the mechanistic level have been described in the case of IBD and cancer. Side effects of IL-10 administration have been reported in both patients and healthy volunteers, but the underlying mechanisms remain unknown. The human figure represents clinical data, and the mouse figure preclinical findings. HCV, hepatitis C virus.](JEM_20190418_Fig4){#fig4}

Enhancing IL-10 in inflammatory bowel disease (IBD) {#s15}
---------------------------------------------------

IBD is perhaps the best studied disease in the context of IL-10, owing to the initial findings that IL-10--deficient mice develop colitis ([@bib120]), together with the profound genetic association of IBD with deficient IL-10 responses ([@bib73], [@bib74], [@bib75]; [@bib106]; [@bib163]; [@bib55]; [@bib53]). Administration of IL-10 or IL-10 overexpression in different animal models of colitis has proved consistently beneficial ([@bib82]; [@bib217]; [@bib24]). In humans, systemic (intravenous or subcutaneous) administration of recombinant IL-10 has been tested to treat IBD in different trials, but in general it did not significantly improve the clinical outcome of the patients ([@bib231]; [@bib57]; [@bib208]; [@bib35]). A likely explanation for this relies on the possible low concentration of IL-10 achieved locally. Thus, efforts have been placed in designing strategies to specifically deliver IL-10 to the intestine. An interesting approach has been the development of bacteria engineered for intestinal IL-10 delivery. Specifically, the dairy microbe *Lactococcus lactis* has been modified to express the *Il10* gene and intragastrically administered to mice ([@bib217]). This strategy has proved efficient in dextran sulfate sodium--induced and spontaneous (IL-10--deficient) colitis models ([@bib217]). Subsequent improvements of the engineered *L. lactis* have been devised, all with positive effects in ameliorating experimental colitis (reviewed in [@bib211]; [@bib240]). Genetic modification of *Bifidobacterium bifidum* for IL-10 expression has also been described ([@bib154]), thus expanding the species of bacteria amenable for IL-10 intestinal delivery. Although only tested in a small cohort of Crohn's disease patients, therapeutic *L. lactis* expressing human IL-10 ameliorated the clinical score of disease ([@bib17]), which, together with the promising findings obtained in the mouse model, suggests that further improving these approaches may render them applicable for human therapy.

IL-10 as an immunotherapy for cancer {#s16}
------------------------------------

The immunosuppressive role of IL-10 has led to the general view that its presence during cancer would facilitate tumor immune escape ([@bib51]). This hypothesis is validated in several animal models. Overexpression of IL-10 resulted in failure to control an immunogenic tumor ([@bib82]), and blockade of IL-10Rα increased the therapeutic benefit of chemotherapy in a breast cancer model ([@bib201]) and to other transplantable tumors in the context of CpG immunostimulatory oligonucleotide by reversal of tumor-induced DC paralysis ([@bib235]). Likewise, IL-10 deficiency conferred resistance to UV-induced skin carcinogenesis ([@bib141]). In patients, the presence of IL-10 has been described in the tumor-microenvironment of different cancers and overall correlated with poor prognosis ([@bib176]; [@bib147]; reviewed in [@bib179]). However, early lines of evidence suggest an unanticipated protective role for IL-10 in cancer. Both IL-10 overexpression and IL-10 administration have been reported to associate with tumor shrinkage and rejection ([@bib14]; [@bib261]; [@bib80]). More recently, administration of pegylated IL-10 to mouse models of breast cancer or squamous cell carcinoma provided compelling preclinical evidence on the efficacy of IL-10 as an immunotherapy for cancer ([@bib164]). Mechanistically, IL-10 increased CD8 T cell infiltration in tissue, induced IFN-γ production, and favored effective T cell memory responses ([@bib164]; [@bib54]). Prompted by these studies, a pegylated human IL-10 was developed ([@bib171]) and shown to induce hallmarks of CD8 T cell immunity in patients with solid tumors ([@bib172]). Thus, IL-10 may in some types of cancer be useful as an immunotherapy by potentiating the activity of antitumor CD8 T cells (reviewed in [@bib8]; [@bib183]; [@bib240]). However, a recent study has shown that tumor-infiltrating regulatory T cells through their expression of IL-10 and IL-35 may contribute to the exhaustion of intratumoral CD8 T cells, via the up-regulation of the transcription factor Blimp-1 ([@bib206]). Several factors may explain the discrepancies between these different studies, including the cell targeted by IL-10 in the different tumors (for example, myeloid versus T cell), or differences in the T cell response to IL-10 at different effector stages. Thus, it is critical to determine the context whereby IL-10 may provide a protective or detrimental role in the treatment of tumors, in order to appropriately tailor cancer therapy.

The potential of IL-10 to treat other diseases {#s17}
----------------------------------------------

In addition to IBD and cancer, the therapeutic manipulation of IL-10 has been envisaged in the context of several other pathologies (reviewed in [@bib179]; [@bib183]; [@bib240]). In both rheumatoid arthritis and psoriasis, IL-10 administration has yielded some promising results at the preclinical and clinical levels ([@bib156]; [@bib229]; [@bib65]). In allergic asthma, where pathological responses to inhaled allergens develop due to a failure of immune tolerance, successful therapeutic strategies are linked to an increase of IL-10. This is the case for the glucocorticoid dexamethasone, which favors IL-10 production by human CD4 and CD8 T cells ([@bib197]; [@bib12]). Furthermore, severe steroid-resistant asthma associates with failure of patient cells to enhance IL-10 in response to dexamethasone ([@bib253]; [@bib81]). A recent study showed that the dexamethasone-driven IL-10 production by human memory CD4 T cells is accompanied by that of IL-17A, IL-17F, and IL-22. However, the presence of high doses of IL-2 skewed the response to dexamethasone toward single IL-10--producing cells ([@bib146]). Therefore, combined therapies that enhance glucocorticoid-driven IL-10 production in the absence of IL-17 are of potential interest in asthma. Several strategies to enhance IL-10 in the context of neurological disorders with an immune component have also been developed (reviewed in [@bib138]; [@bib20]). These included administration of recombinant IL-10, enhancement of IL-10 production through agonists, or delivery of IL-10 through viral vectors (reviewed in [@bib122]). However, the preclinical success of IL-10 in this setting has been conflicting, and targeting IL-10 to treat neuroimmune disorders has not been tested in the clinic. An opposing strategy consists of IL-10 blockade, in pathologies where its excess is detrimental. This is the case of systemic lupus erythematous. A small clinical trial performed in systemic lupus erythematous patients showed an improvement of symptoms following IL-10 blockade ([@bib137]).

Given the anti-inflammatory action of IL-10, its therapeutic manipulation in infection is appealing. However, the effects of IL-10 in infection significantly depend on the infecting agent (reviewed in [@bib38]; [@bib196]). In a number of experimental models of infection including *T. gondii* ([@bib69]), malaria ([@bib131]), and *Trypanosoma cruzi* ([@bib89]), ablation of IL-10 led to minimal pathogen clearance, while allowing fatal tissue damage. Interestingly, administration of IL-10 to a small cohort of chronic hepatitis C patients who had not previously responded to IFN-based therapies did not impact antiviral activity and resulted in improved liver histology and function, as well as in reduced liver fibrosis in a large proportion of patients receiving treatment ([@bib175]). In studies using experimental models of *Listeria monocytogenes* ([@bib44]), lymphocytic choriomeningitis virus ([@bib18]), *Leishmania major* ([@bib13]), *Leishmania donovani* ([@bib170]), and *M. tuberculosis* ([@bib195]), IL-10 deficiency resulted in increased pathogen clearance, beneficial to the host. In the case of tuberculosis, both human and mouse studies highlight a role for IL-10 in limiting the host protective immune response (reviewed in [@bib196]). Interestingly, a recent study has shown that the delivery of aerosolized peptide inhibitors targeting the IL-10/STAT3 pathway to mice chronically infected with *M. tuberculosis* led to a reduction of bacterial burden accompanied by the up-regulation of antimicrobial effector molecules and of apoptotic/autophagy mediators ([@bib230]).

Despite the large number of disease settings where IL-10 modulation has been tried, of which we only discussed a few, the overall data are conflicting, and a clear argument in favor of IL-10 as a therapy is still nonexistent. Several variables need to be fine-tuned, including the anatomical location where IL-10 is needed for treatment and the context of diseases where IL-10 has a stimulatory or anti-inflammatory effect.

Secondary effects associated with increased doses of IL-10 {#s18}
----------------------------------------------------------

Most data assessing the side effects of IL-10 administration have been obtained in the context of systemic administration of recombinant IL-10 to Crohn's disease patients. The overall results show that systemic administration of recombinant IL-10 is well-tolerated, particularly at low doses ([@bib231]). However, when higher doses of IL-10 were administered, some unexpected side effects have been observed ([Fig. 4](#fig4){ref-type="fig"}), including fatigue and headache, accompanied by a reduction of red blood cells and thrombocytes ([@bib21]). Additionally, the induction of the pro-inflammatory cytokine IFN-γ and decreased hemoglobin and platelet counts have been reported ([@bib228]). Similar side effects have been described during the administration of recombinant IL-10 to treat psoriatic arthritis ([@bib156]). Importantly, these effects seemed to be reversible ([@bib227]) and did not appear to be disease-related, as even in healthy volunteers, an up-regulation of IFN-γ in the serum has been observed ([@bib126]). The mechanisms underlying this immune-stimulatory role of IL-10 remain unknown. It has been suggested that the observed anemia might be caused by an IL-10--driven deregulation of iron metabolism ([@bib227]). Whether the up-regulation of IFN-γ and granzyme B result from the activation of CD8 T cells, as shown in the case of pegylated IL-10, or from alternative mechanisms remains unknown. More research is needed to elucidate the aforementioned effects of IL-10, as they may provide key insights on combinatory therapies to increase the efficacy of IL-10 in inflammatory conditions.

Concluding remarks {#s19}
==================

The wide range of IL-10--producing and IL-10--responding cells offers the immune system the possibility of regulating the immune response in different situations and anatomical sites. However, its opposing context-specific anti-inflammatory and stimulatory effects make the therapeutic manipulation of IL-10 challenging. Progress in this area will require a deeper understanding of IL-10 biology, specifically of the molecular mechanisms that govern IL-10 production and action, as well as of the contrasting roles this cytokine may play in different contexts. Also important will be obtaining information on nonclassic functions of IL-10, which are only now being unveiled. Given the history of IL-10 research, exciting new findings on the biology of this cytokine are expected in the future.
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